Pliant stock surges ~50% as drug shows promise in mid-stage study for lung disorder

Modern Medical Research Laboratory: Portrait of Latin and Black Young Scientists Using Microscope, Digital Tablet, Doing Sample Analysis, Talking. Diverse Team of Specialists work in Advanced Lab


Pliant Therapeutics (NASDAQ:PLRX) reported 12-week interim knowledge for its drug bexotegrast’s 320 mg dose group in a part 2a trial to deal with sufferers with a sort of lung illness known as idiopathic pulmonary fibrosis (IPF).

The study, dubbed, INTEGRIS-IPF, is evaluating bexotegrast (PLN-74809) at once-daily doses

Source link

5 Trading strategies to make money

Looking to boost your trading profits?

Get you copy of our FREE Ebook Now !!!